Skip Navigation

University of California-Davis: Dataset Details, ID=GSE28359

Superfund Research Program

Development and Application of Integrated In Vitro and Cell-Based Bioassays

Project Leader: Michael S. Denison
Co-Investigator: Isaac N. Pessah
Grant Number: P42ES004699
Funding Period: 1995-2015
View this project in the NIH Research Portfolio Online Reporting Tools (RePORT)

Project-Specific Links

Connect with the Grant Recipients

Visit the grantee's eNewsletter page Visit the grantee's Facebook page

Title: Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells

Accession Number: GSE28359

Link to Dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28359

Repository: Gene Expression Omnibus (GEO)

Data Type(s): Gene Expression

Experiment Type(s): Expression profiling by array

Organism(s): Homo sapiens

Summary: "Although practiced clinically for more than 40 years, the use of hematopoietic stem cell (HSC) transplants remains limited by the ability to expand these cells ex vivo. An unbiased screen with primary human HSCs identified a purine derivative, StemRegenin 1 (SR1), that promotes the ex vivo expansion of CD34+ cells. Culture of HSCs with SR1 led to a 50-fold increase in cells expressing CD34 and a 17-fold increase in cells that retain the ability to engraft immunodeficient mice. Mechanistic studies show that SR1 acts by antagonizing the aryl hydrocarbon receptor (AHR). The identification of SR1 and AHR modulation as a means to induce ex vivo HSC expansion should facilitate the clinical use of HSC therapy. LGC006, a less potent SR1 analog, was also examined."

Publication(s) associated with this dataset:
  • Boitano A, Wang J, Romeo R, Bouchez L, Parker A, Sutton SE, Walker J, Flaveny C, Perdew GH, Denison MS, Schultz P, Cooke M. 2010. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329(5997):1345-1348. doi:10.1126/science.1191536 PMID:20688981 PMCID:PMC3033342
Back
to Top